MedTrace Logo

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

NCT00533312 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 407

Last updated 2017-04-07

No results posted yet for this study

Summary

A study to determine lipid changing effects of MK0524A when compared to niacin extended release (NIASPAN) and placebo.

Conditions

Interventions

DRUG

Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks

DRUG

MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks

DRUG

Comparator : niacin / Duraton of Treatment: 4 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2005-07-31
Completion
2007-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533312 on ClinicalTrials.gov